|
WO1999001124A1
(en)
*
|
1996-12-03 |
1999-01-14 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
DK1399484T3
(da)
*
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
|
ES2263984T3
(es)
*
|
2002-06-28 |
2006-12-16 |
Domantis Limited |
Ligandos doble-especificos con una vida media serica aumentada.
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
DE60330407D1
(de)
|
2002-08-23 |
2010-01-14 |
Sloan Kettering Inst Cancer |
Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
KR100872204B1
(ko)
*
|
2003-10-15 |
2008-12-09 |
오에스아이 파마슈티컬스, 인코포레이티드 |
이미다조피라진 티로신 키나제 억제제
|
|
JP2007510434A
(ja)
|
2003-11-12 |
2007-04-26 |
シェーリング コーポレイション |
多重遺伝子発現のためのプラスミドシステム
|
|
US8017321B2
(en)
|
2004-01-23 |
2011-09-13 |
The Regents Of The University Of Colorado, A Body Corporate |
Gefitinib sensitivity-related gene expression and products and methods related thereto
|
|
ATE514434T1
(de)
|
2004-02-25 |
2011-07-15 |
Dana Farber Cancer Inst Inc |
Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
|
|
TWI378934B
(en)
*
|
2004-04-02 |
2012-12-11 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
|
WO2005117553A2
(en)
*
|
2004-05-27 |
2005-12-15 |
The Regents Of The University Of Colorado |
Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
|
|
EP1755608A1
(en)
*
|
2004-06-03 |
2007-02-28 |
F.Hoffmann-La Roche Ag |
Treatment with gemcitabine and an egfr-inhibitor
|
|
EP2283831A3
(en)
|
2004-12-03 |
2013-10-23 |
Merck Sharp & Dohme Corp. |
Biomakers for pre-selection of patients for anti-IGF1R therapy
|
|
JP2008535790A
(ja)
*
|
2005-03-03 |
2008-09-04 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
|
|
US8383357B2
(en)
*
|
2005-03-16 |
2013-02-26 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
|
CA2601157A1
(en)
|
2005-03-16 |
2006-09-28 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
|
KR20080019249A
(ko)
|
2005-06-15 |
2008-03-03 |
쉐링 코포레이션 |
안정한 항체 제형
|
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US8088928B2
(en)
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
EP1910385B1
(en)
*
|
2005-08-04 |
2013-07-24 |
Sirtris Pharmaceuticals, Inc. |
Benzothiazoles and thiazolopyridines as sirtuin modulators
|
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
|
AU2006292278B2
(en)
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
CA2632866A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
|
WO2007117400A2
(en)
*
|
2006-03-31 |
2007-10-18 |
Janssen Pharmaceutica N.V. |
Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
|
|
WO2007117399A2
(en)
|
2006-03-31 |
2007-10-18 |
Janssen Pharmaceutica N.V. |
Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
|
|
US20080045589A1
(en)
*
|
2006-05-26 |
2008-02-21 |
Susan Kelley |
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
|
|
EP2120932B1
(en)
*
|
2006-12-20 |
2014-07-09 |
Nerviano Medical Sciences S.r.l. |
Indazole derivatives as kinase inhibitors for the treatment of cancer
|
|
US20090068110A1
(en)
*
|
2006-12-22 |
2009-03-12 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
|
TW200900070A
(en)
*
|
2007-02-27 |
2009-01-01 |
Osi Pharm Inc |
Combination cancer therapy
|
|
JP5240739B2
(ja)
*
|
2007-04-13 |
2013-07-17 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
|
WO2008149147A2
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
TW200916472A
(en)
|
2007-06-20 |
2009-04-16 |
Sirtris Pharmaceuticals Inc |
Sirtuin modulating compounds
|
|
JP2011501660A
(ja)
*
|
2007-10-03 |
2011-01-13 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
|
|
JP2010540960A
(ja)
*
|
2007-10-03 |
2010-12-24 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
|
|
JP2011502984A
(ja)
*
|
2007-11-01 |
2011-01-27 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
サーチュインモジュレーターとしてのアミド誘導体
|
|
CA2705138A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Sirtris Pharmaceuticals, Inc. |
Solubilized thiazolopyridines
|
|
WO2009079001A1
(en)
|
2007-12-18 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
|
|
DK2082745T3
(da)
|
2007-12-28 |
2013-03-25 |
Deutsches Krebsforsch |
Kræftterapi med en parvovirus kombineret med kemoterapi
|
|
JP2011510018A
(ja)
*
|
2008-01-18 |
2011-03-31 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
癌治療のためのイミダゾピラジノール誘導体
|
|
RU2008106419A
(ru)
*
|
2008-02-21 |
2009-08-27 |
Закрытое акционерное общество "Ива фарм" (RU) |
Лекарственные средства на основе олигоядерных координационных соединений d-металлов, способ терапевтического воздействия на организм пациента и способ повышения терапевтической эффективности фармакологически активного вещества
|
|
KR101189883B1
(ko)
|
2008-03-27 |
2012-10-10 |
미쓰비시덴키 가부시키가이샤 |
엘리베이터의 제어 시스템
|
|
EP2283020B8
(en)
*
|
2008-05-19 |
2012-12-12 |
OSI Pharmaceuticals, LLC |
Substituted imidazopyr-and imidazotri-azines
|
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
|
EP2376502B1
(en)
|
2008-12-19 |
2015-06-17 |
GlaxoSmithKline LLC |
Thiazolopyridine sirtuin modulating compounds
|
|
US20110171124A1
(en)
*
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
WO2010123792A1
(en)
|
2009-04-20 |
2010-10-28 |
Osi Pharmaceuticals, Inc. |
Preparation of c-pyrazine-methylamines
|
|
EP2427192A1
(en)
*
|
2009-05-07 |
2012-03-14 |
OSI Pharmaceuticals, LLC |
Use of osi-906 for treating adrenocortical carcinoma
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
CA2783665A1
(en)
*
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
WO2012117396A1
(en)
*
|
2011-03-01 |
2012-09-07 |
Novotyr Therapeutics Ltd |
Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
JP6255038B2
(ja)
|
2013-02-26 |
2017-12-27 |
トリアクト セラピューティクス，インク． |
癌治療
|
|
PT2964229T
(pt)
|
2013-03-06 |
2020-03-23 |
Janssen Pharmaceutica Nv |
Moduladores de piridina benzimidazol-2-ilo do recetor h4 de histamina
|
|
US9770454B2
(en)
|
2013-07-14 |
2017-09-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
CN112353938A
(zh)
|
2015-02-05 |
2021-02-12 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
GB201617627D0
(en)
*
|
2016-10-18 |
2016-11-30 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
US10479786B2
(en)
*
|
2016-12-13 |
2019-11-19 |
Princeton Drug Discovery, Inc |
Protein kinase inhibitors
|